Stockreport

Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 [Yahoo! Finance]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF Revenue : Generated $0.2 million in revenue for the full year 2023 from a manufacturing technology transfer agreement. R&D Expenses : Research and development expense [Read more]